What the company does
OSCOTECInc is a South Korean biotech company, listed on KOSDAQ, that develops synthetic small-molecule drugs for conditions such as arthritis and cancer, while also supplying functional health-food ingredients and dental bone-graft materials used in dental procedures.
Its products reach domestic pharmaceutical companies, dentists, and health-food manufacturers. The business runs three parallel lines, drug discovery, functional ingredients, and dental bone grafts, with a targeted lung-cancer compound that has been approved by both the Korean drug regulator and the US FDA as a first-line treatment, either alone or in combination.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$3.6M
- FY2024US$24.6M
- FY2025US$72.3M
Operating profit
- FY2023−US$23.7M
- FY2024−US$2M
- FY2025US$37.7M
Net income
- FY2023−US$20.6M
- FY2024−US$1.2M
- FY2025US$39.4M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The lung-cancer compound was licensed out to a domestic pharmaceutical company through a technology-transfer agreement, making licensing a key part of its drug-development model.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?